Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Jun 11, 2024
Product Development
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout
Plus: Bluejay, Vir give HDV updates; Skye’s miss in glaucoma; and more
BioCentury | May 10, 2024
Product Development
Epigenetic editors at ASGCT: animal models address the durability question
As the new modality advances, the promise of durability is bearing out in preclinical models
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Jul 21, 2023
Product Development
Vir’s first shot at ‘day one solution’ for influenza A misses Phase II endpoints
Prophylactic mAb was positioned as a bulwark against a potential flu pandemic
BioCentury | Apr 4, 2023
Product Development
With De Backer on board, Vir shares views on partnerships, prophylaxis
Vir’s new CEO thinks its prophylactic influenza mAb, due to read out mid-year, could be a ‘day one solution’ for a flu pandemic
BioCentury | Mar 3, 2023
Finance
March 2 Quick Takes: MorphoSys laying off staff, ending preclinical work
Plus: Flamingo teaming up with Dynacure and updates from Debiopharm, Aldeyra, Checkpoint and more
BioCentury | Jan 25, 2023
Management Tracks
Phase II readouts will inform De Backer’s choices as she succeeds Scangos at Vir
Incoming CEO with extensive BD background will inherit strong balance sheet as data are due from HBV, HDV, flu studies
BioCentury | Nov 10, 2022
Deals
Nov. 9 Quick Takes: Royalty deal brings Arrowhead $250M as partner Amgen preps Phase III
Plus: Bankruptcy ‘increasingly probable’ for Clovis, and updates from Veru, SOBI, GSK and more
Items per page:
1 - 10 of 276